BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9341144)

  • 21. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes.
    Nykjaer A; Conese M; Christensen EI; Olson D; Cremona O; Gliemann J; Blasi F
    EMBO J; 1997 May; 16(10):2610-20. PubMed ID: 9184208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of ligand binding to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that lipoprotein lipase and the carboxyl-terminal domain of the receptor-associated protein bind to the same site.
    Nielsen MS; Nykjaer A; Warshawsky I; Schwartz AL; Gliemann J
    J Biol Chem; 1995 Oct; 270(40):23713-9. PubMed ID: 7559542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
    Okada SS; Grobmyer SR; Barnathan ES
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.
    Conese M; Olson D; Blasi F
    J Biol Chem; 1994 Jul; 269(27):17886-92. PubMed ID: 8027043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential regulation of urokinase-type-1 inhibitor complex endocytosis by phorbol esters in different cell lines is associated with differential regulation of alpha 2-macroglobulin receptor and urokinase receptor expression.
    Kjøller L; Simonsen AC; Ellgaard L; Andreasen PA
    Mol Cell Endocrinol; 1995 Apr; 109(2):209-17. PubMed ID: 7664984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes.
    Higazi AA; Bdeir K; Hiss E; Arad S; Kuo A; Barghouti I; Cines DB
    Blood; 1998 Sep; 92(6):2075-83. PubMed ID: 9731065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein.
    Willnow TE; Orth K; Herz J
    J Biol Chem; 1994 Jun; 269(22):15827-32. PubMed ID: 7515061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of the heparin and low density lipid receptor-related protein-binding sites of protease nexin 1 (PN1) in urokinase-PN1 complex catabolism. The PN1 heparin-binding site mediates complex retention and degradation but not cell surface binding or internalization.
    Crisp RJ; Knauer DJ; Knauer MF
    J Biol Chem; 2000 Jun; 275(26):19628-37. PubMed ID: 10867020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
    Liang OD; Chavakis T; Kanse SM; Preissner KT
    J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.
    Liu CX; Li Y; Obermoeller-McCormick LM; Schwartz AL; Bu G
    J Biol Chem; 2001 Aug; 276(31):28889-96. PubMed ID: 11384978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids.
    Komissarov AA; Florova G; Azghani A; Karandashova S; Kurdowska AK; Idell S
    Am J Physiol Lung Cell Mol Physiol; 2013 Nov; 305(10):L682-92. PubMed ID: 23997178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V
    J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.
    Poliakov A; Tkachuk V; Ovchinnikova T; Potapenko N; Bagryantsev S; Stepanova V
    Biochem J; 2001 May; 355(Pt 3):639-45. PubMed ID: 11311125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
    Behrendt N; List K; Andreasen PA; Danø K
    Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator.
    Frenette G; Tremblay RR; Lazure C; Dube JY
    Int J Cancer; 1997 May; 71(5):897-9. PubMed ID: 9180162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear translocation of urokinase-type plasminogen activator.
    Stepanova V; Lebedeva T; Kuo A; Yarovoi S; Tkachuk S; Zaitsev S; Bdeir K; Dumler I; Marks MS; Parfyonova Y; Tkachuk VA; Higazi AA; Cines DB
    Blood; 2008 Jul; 112(1):100-10. PubMed ID: 18337556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.